Nuformix PLC Result of AGM
20 März 2025 - 12:10PM
RNS Regulatory News
RNS Number : 5163B
Nuformix PLC
20 March 2025
20 March 2025
Nuformix plc
("Nuformix" or the "Company")
Result of Annual General
Meeting
Nuformix plc (LSE: NFX), a pharmaceutical
development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing, announces that the Annual General
Meeting ("AGM") of Nuformix plc was held earlier today and all
resolutions put to shareholders were duly passed by a show of
hands. The proxy votes received were as follows:
|
|
Resolution
|
Ordinary/Special
|
For
|
|
Against
|
|
Total votes cast
|
|
|
|
|
No. of
votes
|
%
|
No. of
votes
|
%
|
No. of
votes
|
|
1
|
To receive the Company's annual report and
accounts
|
Ordinary
|
88,884,205
|
99.5
|
449,137
|
0.5
|
89,333,342
|
|
2
|
To approve the Directors' Remuneration
Policy
|
Ordinary
|
87,134,389
|
98.05
|
1,732,136
|
1.95
|
88,866,525
|
|
3
|
To approve the remuneration report
|
Ordinary
|
87,134,389
|
98.07
|
1,712,636
|
1.93
|
88,847,025
|
|
4
|
That Dr Daniel Gooding be re-appointed as a
Director
|
Ordinary
|
88,672,332
|
99.51
|
433,313
|
0.49
|
89,105,645
|
|
5
|
That Dr Julian Gilbert be re-appointed as a
Director
|
Ordinary
|
88,632,832
|
99.49
|
453,313
|
0.51
|
89,086,145
|
|
6
|
That Ms Madeleine Kennedy be re-appointed as a
Director
|
Ordinary
|
88,620,969
|
99.50
|
441,479
|
0.50
|
89,062,448
|
|
7
|
To re-appoint Kreston Reeves LLP as auditor of
the Company
|
Ordinary
|
88,819,667
|
99.60
|
352,795
|
0.40
|
89,172,462
|
|
8
|
To authorise the Directors to determine the
auditor's remuneration
|
Ordinary
|
87,612,217
|
98.51
|
1,321,125
|
1.49
|
88,933,342
|
|
9
|
To authorise the Directors to allot
securities
|
Ordinary
|
84,636,256
|
94.81
|
4,630,269
|
5.19
|
89,266,525
|
|
10
|
To authorise the Directors to
disapply pre-emption rights
|
Special
|
85,436,025
|
95.86
|
3,686,005
|
4.14
|
89,122,030
|
|
11
|
To authorise the Company to purchase its own
shares
|
Special
|
87,796,808
|
98.88
|
992,039
|
1.12
|
88,788,847
|
|
12
|
To authorise calling of a general meeting on 14
clear days' notice
|
Special
|
88,600,047
|
99.18
|
733,295
|
0.82
|
89,333,342
|
A vote withheld is not a vote in law and is not
counted in the calculation of votes validly cast for or against a
resolution.
The Company's issued share capital is
1,669,309,368 ordinary shares of 0.05p
each.
Enquiries:
|
Nuformix plc
Dr Daniel Gooding, Executive
Director
|
Via IFC Advisory
|
|
CMC
Markets
Douglas Crippen
|
+44 (0) 20 3003 8632
|
|
IFC
Advisory Limited
Tim Metcalfe
Zach Cohen
|
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
|
About Nuformix
Nuformix is a pharmaceutical
development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug
forms, with improved physical properties, to develop new products
in new indications that are, importantly, differentiated from the
original (by way of dosage, delivery route or presentation), thus
creating new and attractive commercial opportunities. Nuformix has
a pipeline of preclinical assets with potential for significant
value and early licensing opportunities.
For more information, please
visit www.nuformix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGFBLFLEXLBBBK
Nuformix (LSE:NFX)
Historical Stock Chart
Von Mär 2025 bis Apr 2025
Nuformix (LSE:NFX)
Historical Stock Chart
Von Apr 2024 bis Apr 2025
